The value of SARS-CoV-2 serology testing and the role of neutralization
26 Oct 2020
SARS-CoV-2, the causative agent of COVID-19, has resulted in a global pandemic. Serology assays can be used for discerning seroprevalence, screening volunteers for vaccine trials and convalescent plasma donations, as well as predicting infection or vaccine-induced immunity.
Several commercially available SARS-CoV-2 immunoassays have been evaluated for their sensitivity and further studies have evaluated the role of the antigen target in its ability to assess protection against reinfection.
Public health strategies going forward will be based on the ability to answer a) how circulating antibody levels that are specific for each viral antigen change with time following natural infection and b) which serological assays best predict protective immunity.
Following this webinar, you will be able to:
- Describe the role serology plays in the clinician toolbox for managing COVID-19
- Differentiate the difference between the neutralization capabilities of assays that target the nucleocapsid versus the spike protein
- Explain the importance of long-term kinetics of antibody titers and the corresponding effectiveness of commercial assays in correctly interpreting testing protocols